BR112012010026A2 - dispositivo oculares de entrega de drogas - Google Patents

dispositivo oculares de entrega de drogas

Info

Publication number
BR112012010026A2
BR112012010026A2 BR112012010026A BR112012010026A BR112012010026A2 BR 112012010026 A2 BR112012010026 A2 BR 112012010026A2 BR 112012010026 A BR112012010026 A BR 112012010026A BR 112012010026 A BR112012010026 A BR 112012010026A BR 112012010026 A2 BR112012010026 A2 BR 112012010026A2
Authority
BR
Brazil
Prior art keywords
polymer
solvent
api
variety
drug delivery
Prior art date
Application number
BR112012010026A
Other languages
English (en)
Other versions
BR112012010026B8 (pt
BR112012010026B1 (pt
Inventor
Theresa Jacob Jean
John Halloran Kevin
Mckee Yuri
Original Assignee
Aton Pharma Inc
Louisiana State Univ Agricultural And Mechanical College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aton Pharma Inc, Louisiana State Univ Agricultural And Mechanical College filed Critical Aton Pharma Inc
Publication of BR112012010026A2 publication Critical patent/BR112012010026A2/pt
Publication of BR112012010026B1 publication Critical patent/BR112012010026B1/pt
Publication of BR112012010026B8 publication Critical patent/BR112012010026B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L1/00—Compositions of cellulose, modified cellulose or cellulose derivatives
    • C08L1/08—Cellulose derivatives
    • C08L1/26—Cellulose ethers
    • C08L1/28—Alkyl ethers
    • C08L1/284—Alkyl ethers with hydroxylated hydrocarbon radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Polymers & Plastics (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

dispositivo oculares de entrega de drogas. um método de formação de um dispositivo de administração ocular inclui expondo um sólido, polímero de celulose em forma de uma solução incluindo um ingrediente farmacêutico ativo (api) e um solvente capaz de solubilizar o api, em que o polímero absorve pelo menos uma porção da solução, incluindo o api e solvente. o método pode ainda incluir removendo pelo menos uma porção do solvente absorvido a partir do polímero, permitindo que o solvente se evapore absorvido a partir do polímero ou por secagem do polímero. uma variedade de polímeros de celulose podem ser utilizados, incluindo hidroxipropilcelulose. uma variedade de apis podem ser utilizados, incluindo tobramicina ciclosporina, e vancomicina. dispositivos oculares de entrega preparados pelos métodos podem ser usados para tratar uma variedade de desordens oculares.
BR112012010026A 2009-10-30 2010-10-29 método de formação de um dispositivo de liberação ocular e dispositivo de liberação ocular BR112012010026B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US25691509P 2009-10-30 2009-10-30
US61/256,915 2009-10-30
US39104010P 2010-10-07 2010-10-07
US61/391,040 2010-10-07
PCT/US2010/054823 WO2011053841A1 (en) 2009-10-30 2010-10-29 Ocular drug delivery devices

Publications (3)

Publication Number Publication Date
BR112012010026A2 true BR112012010026A2 (pt) 2017-07-04
BR112012010026B1 BR112012010026B1 (pt) 2020-10-27
BR112012010026B8 BR112012010026B8 (pt) 2021-02-02

Family

ID=43922594

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012010026A BR112012010026B8 (pt) 2009-10-30 2010-10-29 método de formação de um dispositivo de liberação ocular e dispositivo de liberação ocular

Country Status (8)

Country Link
US (3) US20110129516A1 (pt)
EP (1) EP2493459B1 (pt)
JP (1) JP5886204B2 (pt)
BR (1) BR112012010026B8 (pt)
CA (1) CA2779104C (pt)
ES (1) ES2603057T3 (pt)
PL (1) PL2493459T3 (pt)
WO (1) WO2011053841A1 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7431710B2 (en) 2002-04-08 2008-10-07 Glaukos Corporation Ocular implants with anchors and methods thereof
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
US10245178B1 (en) 2011-06-07 2019-04-02 Glaukos Corporation Anterior chamber drug-eluting ocular implant
AU2012339695B2 (en) * 2011-11-15 2017-10-05 Allergan, Inc. Sustained action formulation of cyclosporin Form 2
EP3013790A1 (en) 2013-06-27 2016-05-04 Mylan Laboratories Ltd. Process for the preparation of nepafenac
WO2015184173A1 (en) 2014-05-29 2015-12-03 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
US11925578B2 (en) 2015-09-02 2024-03-12 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
US11564833B2 (en) 2015-09-25 2023-01-31 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
CN109937025B (zh) 2016-04-20 2022-07-29 多斯医学公司 生物可吸收眼部药物的递送装置
US20180092776A1 (en) 2016-09-30 2018-04-05 Sara Heikali Method and device for treating and managing diseased ocular tissue
US20180318319A1 (en) 2017-05-04 2018-11-08 Ocular Science, Inc. Compositions and Methods for Treating Eyes and Methods of Preparation
US11071724B2 (en) 2019-05-17 2021-07-27 Ocular Science, Inc. Compositions and methods for treating presbyopia
BR112021026265A2 (pt) 2019-06-27 2022-06-14 Layerbio Inc Métodos e sistemas de entrega de dispositivos oculares
WO2023214027A1 (en) * 2022-05-06 2023-11-09 Eyed Pharma Insert for the treatment of dry eyes
BE1030504B1 (fr) * 2022-05-06 2023-12-04 Eyed Pharma Insert composite pour le traitement de la sécheresse oculaire
BE1030503B1 (fr) * 2022-05-06 2023-12-04 Eyed Pharma Insert pour le traitement de la sécheresse oculaire

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK137946B (da) * 1973-12-17 1978-06-12 Merck & Co Inc Bæremedium i fast form til anvendelse i ophthalmiske præparater.
US4179497A (en) * 1973-12-17 1979-12-18 Merck & Co., Inc. Solid state ophthalmic medication
US3923939A (en) * 1974-06-07 1975-12-02 Alza Corp Process for improving release kinetics of a monolithic drug delivery device
US4304765A (en) * 1980-10-14 1981-12-08 Alza Corporation Ocular insert housing steroid in two different therapeutic forms
EP0108661A1 (en) * 1982-10-04 1984-05-16 Merck & Co. Inc. Stabilized hydroxypropyl cellulose ophthalmic inserts and process to sterilize the same
US5164188A (en) * 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
US5660851A (en) * 1989-12-26 1997-08-26 Yissum Research Development Company Of The Hebrew Univ. Of Jerusalem Ocular inserts
JP2614409B2 (ja) * 1991-12-20 1997-05-28 ファイザー・インコーポレーテッド 多孔質の付形された放出製剤およびその製造方法
US5443505A (en) * 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US5788687A (en) * 1994-02-01 1998-08-04 Caphco, Inc Compositions and devices for controlled release of active ingredients
JPH0987203A (ja) * 1995-09-27 1997-03-31 Kanegafuchi Chem Ind Co Ltd 薬剤含有粒子及びその製造方法
US6217896B1 (en) * 1999-04-01 2001-04-17 Uab Research Foundation Conjunctival inserts for topical delivery of medication or lubrication
US6331313B1 (en) * 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
US20050013845A1 (en) * 2002-11-12 2005-01-20 Warren Stephen L. Adhesive bioerodible ocular drug delivery system
JP2005187376A (ja) * 2003-12-25 2005-07-14 Shin Etsu Chem Co Ltd 低置換度セルロースエーテル含有カプセル及びその製造方法
US20050244463A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
EP1611877A1 (en) * 2004-06-28 2006-01-04 Universidade de Coimbra Method for preparing sustained-release therapeutic ophthalmic articles using compressed fluids for impregnation of drugs
RU2414193C2 (ru) * 2005-07-29 2011-03-20 Сантен Фармасьютикал Ко., Лтд. Неинвазивная система доставки лекарственного средства к ткани заднего сегмента глаза с применением твердой композиции
WO2008143906A2 (en) * 2007-05-14 2008-11-27 Sustained Nano Systems Llc Hypercompressed particles for controlled release of ophthalmic medications
US9132088B2 (en) * 2008-04-30 2015-09-15 Mati Therapeutics Inc. Composite lacrimal insert and related methods
CA2750242C (en) * 2009-02-12 2018-05-22 Incept, Llc Drug delivery through hydrogel plugs

Also Published As

Publication number Publication date
JP2013509436A (ja) 2013-03-14
CA2779104A1 (en) 2011-05-05
US20140187497A1 (en) 2014-07-03
PL2493459T3 (pl) 2017-06-30
CA2779104C (en) 2018-07-17
JP5886204B2 (ja) 2016-03-16
EP2493459B1 (en) 2016-08-24
WO2011053841A1 (en) 2011-05-05
EP2493459A1 (en) 2012-09-05
ES2603057T3 (es) 2017-02-23
EP2493459A4 (en) 2013-09-04
US20110129516A1 (en) 2011-06-02
BR112012010026B8 (pt) 2021-02-02
BR112012010026B1 (pt) 2020-10-27
US20190133934A1 (en) 2019-05-09
US11730697B2 (en) 2023-08-22

Similar Documents

Publication Publication Date Title
BR112012010026A2 (pt) dispositivo oculares de entrega de drogas
Pereira et al. Polymeric films loaded with vitamin E and Aloe vera for topical application in the treatment of burn wounds
SG10201808743VA (en) Compositions comprising electrohydrodynamically obtained fibres for administration of specific dosages of an active substance to skin or mucosa
MX2016007345A (es) Implante intracameral para el tratamiento de una condicion ocular.
AR111190A1 (es) Composiciones en hidrogel de prodrogas entrecruzadas de ácido hialurónico y métodos relacionados
BRPI0714399B8 (pt) composição farmacêutica líquida oral
BR112014027039A2 (pt) formulação farmacêutica tópica não aquosa; uso de formulação farmacêutica não aquosa; formulação não aquosa; e método
BR112017020511A2 (pt) ?composição de emplastro de microagulha, e, método para tratar uma condição de pele?.
BR112012027672A2 (pt) Dispositivo médico compreendendo um conjunto de microagulhas que se estendem para fora a partir de um suporte e método para formar um dispositivo médico
EP2269666A3 (en) A Medical Device Coating Having an Anti-thrombotic Conjugate
EA200800798A1 (ru) Фармацевтические композиции, предназначенные для лечения нарушений внутреннего уха
AR049979A1 (es) Composicion oftalmica util para la colocacion intraocular en un ojo de un ser humano o animal y uso de un componente corticosteroide, un componente polimerico biocompatible y un componente solvente oftalmicamente compatible en una cantidad efectiva para solubilizar el componente polimerico para prep
BR112015010253A2 (pt) entrega de agentes biologicamente ativos com o uso de solventes hidrofóbicos e voláteis
EA200800161A1 (ru) Новые фармацевтические композиции с модифицированным высвобождением и способ получения таких композиций
BR112015022433A2 (pt) dispositivos de liberação de droga com componente permeável à droga e métodos
BRPI0607483A2 (pt) microimplantes para administração ocular
BR112018072714A2 (pt) composições de ligação a hcl para e método de tratamento de distúrbios de ácido-base
MY167777A (en) A pharmaceutical composition comprising electrohydrodynamically obtained fibres, the composition having improved residence time on the application site
RU2007149249A (ru) Глазные капли, содержащие рофлумиласт
AR051144A1 (es) Procedimiento para formar atorvastatina amorfa
CL2009001080A1 (es) Procedimiento para encapsular agentes biologicamente activos en un vehiculo en forma de particulas, que comprende solubilizar en un agente de apareamiento de ion hidrofobo y un disolvente, disolver, formar la emulsion y obtener el vehiculo; vehiculo en forma de particulas; y composicion farmaceutica que comprende el vehiculo.
BR112012028437A2 (pt) solução oftálmica, e, método para tratar glaucoma ou hipertensão ocular
CO7101247A2 (es) Formulaciones de ácido poliinosínico-policitidílico (poli(i:c)) para el tratamiento de infecciones de las vías respiratorias altas
EP2679253A3 (en) Medical devices based on cellulose
BRPI0815110A8 (pt) sistemas de distribuição para solubilização de ingredientes farmaceuticamente ativos insolúveis em água

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 29/10/2010, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REFERENTE AO DESPACHO 16.1 PUBLICADO NA RPI 2599 DE 27.10.2020, QUANTO AO NOME E ENDERECO DOS TITULARES

B25A Requested transfer of rights approved

Owner name: BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) ; BAUSCH HEALTH IRELAND LIMITED (IE)